| Cash Flow | 2025-09-30 |
|---|---|
| Net loss | -766,409 |
| Loss on disposal of fixed assets | -32 |
| Amortization of intangible assets | 801 |
| Stock-based compensation expense | 84,693 |
| Depreciation and amortization | 5,513 |
| Change in fair value of warrant liabilities and contingent earn-out shares | 2,731 |
| Non-cash interest expense on liability related to sale of future royalties | 12,294 |
| Net amortization of premium or discount on marketable securities | 23,277 |
| Amortization of operating lease right-of-use asset | 5,542 |
| Impairment of assets | 0 |
| Accounts receivable | 0 |
| Prepaid expenses and other current assets | 6,290 |
| Accounts payable | 20,036 |
| Accrued expenses and other current liabilities | 57,663 |
| Operating lease liability | -1,198 |
| Long-term deposits | 4,723 |
| Other noncurrent assets | 12,718 |
| Other noncurrent liabilities | 1,807 |
| Net cash used in operating activities | -623,503 |
| Purchases of marketable securities | 1,498,365 |
| Maturities of marketable securities | 1,549,222 |
| Sales of marketable securities | 6,384 |
| Purchases of property and equipment | 14,065 |
| Net cash provided by (used in) investing activities | 43,176 |
| Proceeds from issuance of common stock upon at-the-market offering, net of issuance costs | 0 |
| Proceeds from issuance of common stock under equity incentive plans | 6,973 |
| Proceeds from issuance of common stock related to employee stock purchase plan | 4,644 |
| Proceeds from the sale of future royalties | 244,215 |
| Exercise of warrants | 4 |
| Deferred offering costs | -29 |
| Net cash provided by financing activities | 255,865 |
| Net decrease in cash, cash equivalents and restricted cash | -324,462 |
| Cash and cash equivalents at beginning of period | 546,762 |
| Cash and cash equivalents at end of period | 222,300 |
Revolution Medicines, Inc. (RVMDW)
Revolution Medicines, Inc. (RVMDW)